✦ LIBER ✦

Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice

✍ Scribed by Mark W. Kunkel; Kenneth E. Hook; Curtis T. Howard; Sally Przybranowski; Billy J. Roberts; William L. Elliott; Wilbur R. Leopold

Publisher: Springer US
Year: 1995
Tongue: English
Weight: 728 KB
Volume: 13
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00873135

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidermal growth factor receptor blockad

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice

✍ Jay P. Overholser; Marie C. Prewett; Andrea T. Hooper; Harlan W. Waksal; Daniel 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 425 KB 👁 1 views

Targeted inhibition of the epidermal gro

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (‘Iressa’) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells

✍ Alessandro Sgambato; Andrea Camerini; Beatrice Faraglia; Raffaele Ardito; Gabrie 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

## Abstract The epidermal growth factor (EGF) plays a role in the development of prostate cancer, which becomes essential after androgen resistance has emerged. The EGF receptor (EGFR) is therefore a potential target for anticancer therapy. We evaluated the effects of ZD1839 (‘Iressa’), an orally a

Inhibition of Ca2+/calmodulin-dependent

Inhibition of Ca2+/calmodulin-dependent protein kinase or epidermal growth factor receptor tyrosine kinase abolishes lysophosphatidic acid-mediated DNA-synthesis in human myometrial smooth muscle cells

✍ Ulrika K. Nilsson; Samuel P.S. Svensson 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Human myometrial smooth muscle cells (SMCs) were used to evaluate the proliferative activity of lysophosphatidic acid (LPA). This study specifically focuses on the role of Ca(2+)/calmodulin-dependent protein (CaM) kinase and epidermal growth factor (EGF) receptor tyrosine kinase. Myometrial SMCs wer

Phase I dose-finding and pharmacokinetic

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

Prostate cancer cell proliferation is st

Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures

✍ Carlo Vicentini; Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; An 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 416 KB

Inhibition of proliferation and inductio

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant